Navigation Links
GlaxoSmithKline and the University of Edinburgh Agree to Collaborative Partnership for Drug Discovery
Date:10/26/2011

EDINBURGH, Scotland, Oct. 26, 2011 /PRNewswire/ -- GlaxoSmithKline (GSK) and the University of Edinburgh have agreed on a collaborative partnership to discover and develop medicines with the potential to treat severe acute pancreatitis.

The alliance will build on work by university researchers that recently uncovered a molecular mechanism believed to have a major role in triggering life-threatening multiple organ failure. The collaboration will integrate the deep biology and disease understanding of the academic group led by Damian Mole and Dr. Scott Webster of the University's College of Medicine and Veterinary Medicine with GSK's expertise in drug discovery and development.

"Despite treatment for severe acute pancreatitis, up to a quarter of people affected will die from an attack. By teaming up with GSK, we have the opportunity to turn our science into a medicine," said Mole. Webster added, "This is a great example of translating academic research. The alliance brings together our collective expertise in target biology and drug discovery to tackle an enormous unmet medical need."

Work on the project will be carried out both within GSK and at the College of Medicine and Veterinary Medicine located at the Edinburgh BioQuarter (http://bit.ly/tfrXA7), Scotland's flagship life sciences development.

Under the terms negotiated by the BioQuarter, the University will receive success-based financial support from GSK linked to reaching agreed milestones, as well as an undisclosed upfront payment and royalties on sales from any product that is successfully commercialized out of the collaboration.

This alliance comes through GSK's Discovery Partnerships with Academia (DPAc) team, a recently formed group designed to bring together the complementary skill sets of GSK and individual academic groups in the search for innovative medicines.

Dr. Diane Harbison, Head of Business Development at Edinburgh BioQuarter, said: "This collaborative partnership with a world-leader in drug discovery demonstrates the strength and depth of research being conducted here in Edinburgh. We are delighted to have been selected as one of just ten DPAc projects being awarded globally by GlaxoSmithKline."

About Edinburgh BioQuarter

At the heart of Scottish life sciences, Edinburgh BioQuarter is a joint venture between Alexandria Real Estate Equities, Inc, the NHS, the University of Edinburgh and Scottish Enterprise. Edinburgh BioQuarter commercializes world-leading medical research and brings investors, ideas and companies together at the BioQuarter campus on the outskirts of Edinburgh. For more information, visit www.edinburghbioquarter.com.


'/>"/>
SOURCE Edinburgh BioQuarter
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ian Tomlinson Joins SBC Board as GlaxoSmithKline Representative Director
2. Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
3. Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
4. GlaxoSmithKline and Amplimmune Form Global Strategic Collaboration
5. FDA Advisory Committee Makes Favorable Recommendation for Cervarix, GlaxoSmithKlines Candidate Cervical Cancer Vaccine
6. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
7. GlaxoSmithKline Completes Acquisition of Stiefel
8. GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business
9. Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
10. Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes
11. GlaxoSmithKline Reports Q4 and Year End Results 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Calif. (PRWEB) , ... February 24, 2017 , ... Chef ... and wine scene. Making stops in several cities, she gained a number of ... adventure began in Stellenbosch, a town in South Africa’s Western Cape province. It ...
(Date:2/24/2017)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... and CEO, Jim Joyce . In ... Saturday, Bill Gates warned world leaders that ... nuclear weapons. Mr. Gates expressed his concern, which is ... scientific terrorists have access to the necessary tools to ...
(Date:2/24/2017)...  Driven by consumers, preference towards more natural ... growing categories, finds the recently published U.S. volume ... Multi-regional Market Analysis and Opportunities study by ... "Biotechnology actives are derived from natural ... for skin and hair care applications," explains ...
(Date:2/24/2017)... NY (PRWEB) , ... February 24, 2017 , ... FireflySci, ... Founded in late 2014, FireflySci had the goal of bringing their powerful ... goal continues to shape the path that FireflySci is going on as they add ...
Breaking Biology Technology:
(Date:2/13/2017)... 2017 Former 9/11 Commission border counsel and ... Janice Kephart of Identity Strategy Partners, LLP, today ... "Executive Order: Protecting the Nation From Foreign Terrorist ... "As President Trump,s ,Travel Ban, Executive Order gains ... banned the travel ban, it is important that our ...
(Date:2/9/2017)... , Feb. 9, 2017 The biomass boiler ... of the biomass boiler market globally in terms of ... biomass boilers. The market for biomass boilers has been ... end-user, application, and country/region. The market based on feedstock ... forest residues, biogas & energy crops, urban residues, and ...
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
Breaking Biology News(10 mins):